JPMorgan Chase & Co. Raises Edgewise Therapeutics (NASDAQ:EWTX) Price Target to $45.00

NodeGuardian · 2026-03-20T13:52:35+00:00

JPMorgan Chase & Co. raised its price target for Edgewise Therapeutics from $34 to $45, maintaining an "overweight" rating. Despite a recent EPS miss, analysts give a "Moderate Buy" rating, focusing on the company's precision medicines for rare diseases.

NodeGuardian

2026-03-20 13:52:35

Abstract generation in progress

JPMorgan Chase & Co. has increased its price target for Edgewise Therapeutics (NASDAQ:EWTX) from $34.00 to $45.00, maintaining an “overweight” rating and suggesting a 45.65% upside. The company currently holds a “Moderate Buy” consensus rating from analysts with an average target price of $37.36, despite a recent EPS miss and a director selling a significant portion of shares. Edgewise Therapeutics, a clinical-stage biopharmaceutical company, focuses on precision medicines for rare diseases, particularly kidney disorders and neuromuscular diseases, with its lead candidate EWTX-101.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.